WO2024044594A3 - Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic - Google Patents

Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic Download PDF

Info

Publication number
WO2024044594A3
WO2024044594A3 PCT/US2023/072661 US2023072661W WO2024044594A3 WO 2024044594 A3 WO2024044594 A3 WO 2024044594A3 US 2023072661 W US2023072661 W US 2023072661W WO 2024044594 A3 WO2024044594 A3 WO 2024044594A3
Authority
WO
WIPO (PCT)
Prior art keywords
diuretic
combination
methods
treating hypertension
hypertension
Prior art date
Application number
PCT/US2023/072661
Other languages
French (fr)
Other versions
WO2024044594A2 (en
Inventor
David Rodman
Jon CONGLETON
Original Assignee
Mineralys Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mineralys Therapeutics, Inc. filed Critical Mineralys Therapeutics, Inc.
Publication of WO2024044594A2 publication Critical patent/WO2024044594A2/en
Publication of WO2024044594A3 publication Critical patent/WO2024044594A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

This invention provides a method of treating hypertension in a hypertensive subject, the method administering to the subject, an amount of a diuretic and an amount of a CYP 11 β2 beta hydroxylase inhibitor once or twice per day, wherein the amounts taken together are sufficient to treat hypertension in the hypertensive subject when taken in combination with other antihypertensive agents. In particular, the method is sufficient to elicit a safe and robust reduction in hypertension (>10mmHg reduction in systolic blood pressure) in the hypertensive subject.
PCT/US2023/072661 2022-08-23 2023-08-22 Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic WO2024044594A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263400312P 2022-08-23 2022-08-23
US63/400,312 2022-08-23
US202263425803P 2022-11-16 2022-11-16
US63/425,803 2022-11-16

Publications (2)

Publication Number Publication Date
WO2024044594A2 WO2024044594A2 (en) 2024-02-29
WO2024044594A3 true WO2024044594A3 (en) 2024-04-11

Family

ID=90014041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/072661 WO2024044594A2 (en) 2022-08-23 2023-08-22 Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic

Country Status (1)

Country Link
WO (1) WO2024044594A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240641A1 (en) * 2006-05-26 2010-09-23 Julien Papillon Aldosterone Synthase and/or 11B-hydroxylase Inhibitors
US20160221925A1 (en) * 2013-03-15 2016-08-04 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
WO2022093714A1 (en) * 2020-10-26 2022-05-05 Minerals Therapeutics, Inc. Cyp11b2 beta hydroxylase inhibitors for hypertension
WO2023139506A1 (en) * 2022-01-19 2023-07-27 Mineralys Therapeutics, Inc. Methods of treating hypertension by periodic suppression of aldosterone synthase

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100240641A1 (en) * 2006-05-26 2010-09-23 Julien Papillon Aldosterone Synthase and/or 11B-hydroxylase Inhibitors
US20160221925A1 (en) * 2013-03-15 2016-08-04 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
WO2022093714A1 (en) * 2020-10-26 2022-05-05 Minerals Therapeutics, Inc. Cyp11b2 beta hydroxylase inhibitors for hypertension
WO2023139506A1 (en) * 2022-01-19 2023-07-27 Mineralys Therapeutics, Inc. Methods of treating hypertension by periodic suppression of aldosterone synthase

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SYDORCHUK ET AL.: "Association of lipids' metabolism disorders with aldosterone synthase CYP11 B2 (-344CGAMMAGAMMA) gene polymorphism in. hypertensive patients depending on glomerular filtration rate", PHARMACOLOGY, vol. 2, 30 August 2020 (2020-08-30), pages 230 - 242, XP009553021 *

Also Published As

Publication number Publication date
WO2024044594A2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
WO2003057200A3 (en) Compositions comprising inhibitors of dpp-iv and nep enzymes for the treatment of diabetes
WO2005049084A3 (en) Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
EP1212081B8 (en) Use of ace inhibitors in the prevention of congestive heart failure
UA88265C2 (en) Use of inhibitors of the renin-angiotensin system in the prevention of diabetes
WO2003020202A3 (en) Method for reducing hypertension and heart failure
EP1353684B8 (en) Use of inhibitors of dipeptidypeptidase iv (ec 3.3.14.5) and aminopeptidase n (ec 3.4.11.2) for the treatment of neurodegeneration induced by ischaemia
WO2001060348A3 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
WO2003018061A1 (en) Drugs containing chymase inhibitor and ace inhibitor as the active ingredients
WO2002000210A3 (en) Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease
WO2024044594A3 (en) Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic
RS20050461A (en) Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrt) with an inhibitor of cytochrome p450, such as protease inhibitors
Tutuian et al. Esophageal motility disorders (distal esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter): modern management
Karlberg et al. Enalapril and Lisinopril in Renovascular Hypertension Antihypertensne and Hormonal Effects of Two New Angio-Tensin-Converting-Enzyme (ACE) Inhibitors: A Preliminary Report
WO2002053143A3 (en) Treatment of erectile dysfunction with rho-kinase inhibitors
WO2005079772A3 (en) Combination of (s)-amlodipine and an ace inhibitor, and methods for reducing hypertension
WO2006055573A3 (en) Methods of using pde v inhibitors for the treatment of congestive heart failure
WO2003032963A3 (en) Method of reducing type 2 diabetes in high risk patients
Hofstetter et al. The J-Curve Phenomenon
Stergiou et al. A005: Additive hypotensive effect of angiotensin converting enzyme inhibition and angiotensin receptor antagonism in essential hypertension
WO2004075893A8 (en) Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker
WO2004010938A3 (en) Use of chymase inhibitors for the prevention and/or treatment of arterio-venous graft failure
Fariello et al. A004: Candesartan, ABPM and structural--functional parameters in essential hypertensive patients
Zelveian et al. P-569: Influence of sleep related desaturations on nocturnal pulse pressure in patients with mild to moderate hypertension
WO2004004640A3 (en) Methods, compositions and kits for treating damage to excitable tissue
HUP0300661A2 (en) Use of citalopram for treatment of high blood pressure

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23858240

Country of ref document: EP

Kind code of ref document: A2